A novel therapy targeting the gut–liver axis for chronic hepatitis B: Ursodeoxycholic acid plus Bifidobacterium
Background & Aims: Targeting the gut–liver axis is a promising strategy for treating liver diseases. We aimed to assess the therapeutic efficacy of targeting the gut microbiota-bile acid (BA) axis using ursodeoxycholic acid (UDCA) combined with the probiotic Bifidobacterium to treat chronic...
Saved in:
Main Authors: | , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-08-01
|
Series: | JHEP Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S258955592500134X |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|